about
High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.NCCN Task Force Report: Bone Health in Cancer Care.Employment outcomes among survivors of common cancers: the Symptom Outcomes and Practice Patterns (SOAPP) study.Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosisThe importance of nonpharmacogenetic factors in endocrine therapy.Dry eye syndrome in aromatase inhibitor users.
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Safety of aromatase inhibitors in the adjuvant setting.
@ast
Safety of aromatase inhibitors in the adjuvant setting.
@en
type
label
Safety of aromatase inhibitors in the adjuvant setting.
@ast
Safety of aromatase inhibitors in the adjuvant setting.
@en
prefLabel
Safety of aromatase inhibitors in the adjuvant setting.
@ast
Safety of aromatase inhibitors in the adjuvant setting.
@en
P2860
P921
P1476
Safety of aromatase inhibitors in the adjuvant setting.
@en
P2093
Edith A Perez
P2860
P2888
P356
10.1007/S10549-007-9704-7
P407
P478
105 Suppl 1
P577
2007-10-03T00:00:00Z